WuXi Biologics (Cayman) Stock (OTC: WXIBF)

Latest news for WuXi Biologics (Cayman) (OTC:WXIBF) Stock

WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.

Chess,Game,,Two,King,Stand,Confront,On,China,And,Us

Biotech

News

Politics

Global

WUXI BIOLOGICS CAY ORD by Wuxi Biologics Cayman Inc.

WXIBF

U.S. intelligence officials have informed senators that WuXi AppTec, a Chinese pharmaceutical company, allegedly transferred U.S. intellectual property to Beijing without authorization. This news comes amid concerns that certain Chinese biotech firms are providing technology or research and development for use by the Chinese military.

US Intelligence Claims Chinese Pharma Giant Illegally Shared Secrets With Beijing

Intraday Update

Markets

Movers

Trading Ideas

AAPL

AAVXF

ADBE

ADYYF

AFGC

AHCHY

AIQUY

ALFVY

ARES

ASGN

ASGTF

ASML

ASND

ATBYF

ATEYY

ATGN

ATXI

AUPH

AXAHY

AZMTF

BABA

BKFKF

BMRPF

BOLD

BOOT

BTBIF

BURBY

BXMT

CATM

CBRE

CDAY

CGEN

CGPZF

CHNG

CHTR

CODI

CROX

CRUS

CSTL

CTRN

CWXZF

CYDY

DGDM

DIOD

DNNGY

DSDVY

DYFSF

EDPFY

EPAM

ESPR

Eaton Vance Tax-Advantaged Global Dividend

EXPGY

FBMS

FERGY

FFMR

FGBI

FICO

Stocks That Hit 52-Week Highs On Friday

ACRE

ACST

ALGT

APTO

ARCAY

AUBN

BALMF

BLAGF

BWXT

CACI

CATN

CCOI

CIVB

CLPBF

CNXN

CPXWF

DEAC

DRRX

DSGX

EGIF

ELMA

ENTG

ESKYF

FTGFF

FUSB

GFGSF

GOLF

GREN

GRMN

GVDNY

HANNF

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HCMLY

HELE

HESAF

ICLR

IDEXY

IFJPY

IIJIY

IMKTA

INFO

INGIY

INTC

IOVA

IRWD

ITCI

JAZZ

JBAXY

KPTI

LAMR

LBTI

Stocks That Hit 52-Week Highs On Monday

WUXI BIOLOGICS CAY NEW by Wuxi Biologics Cayman Inc.

WuXi Biologics (Cayman) Inc

Carrier Global Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) shares are trading lower after it reported <a href="https://www.benzinga.com/pressreleases/24/07/n39952796/carrier-reports-strong-second-quarter-2024-results" target="_blank" rel="noreferrer noopener">second-quarter FY24 results</a>.
Net sales rose&nbsp;12%&nbsp;Y/Y to&nbsp;$6.70 billion, missing the consensus of&nbsp;$7.00 billion.
Revenue included 2% organic growth and a 12% boost from the Viessmann Climate Solutions acquisition, partially offset by a 2% decline from divestitures.
GAAP operating profit of&nbsp;$3.7 billion&nbsp;was up over&nbsp;650%&nbsp;from last year, primarily due to the gain on the sale of Access Solutions and the addition of Viessmann Climate Solutions.&nbsp;Adjusted operating profit of&nbsp;$1.2 billion&nbsp;was up&nbsp;26%&nbsp;Y/Y,&nbsp;driven by contribution from Viessmann Climate Solutions.
Carrier Chairman &amp; CEO&nbsp;David Gitlin said, &#8220;We delivered solid sales and roughly&nbsp;30%&nbsp;orders growth as we continue to outperform in our markets. Our strong operational execution drove 200 basis points of adjusted operating margin expansion and double-digit adjusted earnings growth.&#8221;
The company reported adjusted EPS of&nbsp;$0.87, beating<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener"> the consensus of&nbsp;$0.84</a>.
Operating cash flow totaled&nbsp;$660 million, and capital expenditures were&nbsp;$111 million, resulting in a free cash flow&nbsp;of&nbsp;$549&nbsp;million.
The company exited the quarter with cash and cash equivalents worth&nbsp;$2.92 billion.
Gitlin added that, &#8220;Year-to-date, we also closed on <a target="_blank" href="https://www.benzinga.com/markets/equities/24/06/39135922/honeywell-takes-flight-boosts-guidance-closes-carrier-global-transaction" rel="noreferrer noopener">two of our four business exits</a>, and the remaining two continue to track well. The proceeds from the exits, combined with our strong free cash flow performance, have enabled us to reduce net debt by about&nbsp;$5 billion&nbsp;in the quarter and we now plan to repurchase about&nbsp;$1 billion&nbsp;of shares in the second half of 2024.&#8221;
FY24&nbsp;Outlook: Carrier reiterated adjusted EPS outlook of&nbsp;$2.80-$2.90&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">versus the&nbsp;$2.86&nbsp;estimate</a>.&nbsp;
The company reduced its sales&nbsp;outlook&nbsp;to ~$25.5 billion&nbsp;from previously expected ~$26 billion&nbsp;(vs.&nbsp;$25.555 billion estimate), with&nbsp;mid-single-digit organic growth.
Carrier reiterated outlook for an adjusted operating margin of&nbsp;15.5%&nbsp;and a free cash flow of ~$0.4 billion.
Investors can gain exposure to the stock via&nbsp;First Trust US Equity Opportunities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FPX#NYSE">FPX</a>) and&nbsp;Carbon Collective Climate Solutions U.S. Equity ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCSO#NASDAQ">CCSO</a>).
Price Action: CARR shares are down 2.73% at $64.19 at the last check Thursday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/39958034" target="_blank" rel="noreferrer noopener">Honeywell Beats On Q2 Earnings, Thanks To Aerospace Strength; Lowers FY24 EPS Outlook</a></li>
</ul>

Earnings

Equities

Guidance

Buybacks

CARR

CCSO

Carrier Global Delivers Mixed Q2 Results, Plan To Repurchase $1B Shares In H2

WIIM

ODFL

Old Dominion Freight Line shares are trading higher after multiple analysts raised their price targets on the stock.

Truist Securities analyst Bill Chappell maintains Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) with a Buy and raises the price target from $65 to $70.

Price Target

Analyst Ratings

Truist Securities Maintains Buy on Coca-Cola, Raises Price Target to $70

Cantor Fitzgerald analyst Sarah James reiterates Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) with a Underweight and maintains $162 price target.

Reiteration

Cantor Fitzgerald Reiterates Underweight on Universal Health Servs, Maintains $162 Price Target

ABBV

AbbVie shares are trading higher after the company reported better-than-expected Q2 financial results and raised its 2024 guidance.

Thermo Fisher shares are trading higher after multiple analysts raised their price targets on the stock following Wednesday's earnings report.

Truist Securities analyst David Macdonald reiterates Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Buy and raises the price target from $155 to $170.

Truist Securities Reiterates Buy on Tenet Healthcare, Raises Price Target to $170

GILD

Gilead Sciences shares are trading higher after the company announced new 5-year data reinforcing Biktarvy as a long term HIV treatment.

Macro Economic Events

Economics

Federal Reserve

U.S. Treasury's Yellen Says BidenAdministration To Continue Commitment To Multilateralism, Building Ties With Allies; Urges Faster Progress On Debt Restructuring For Poor Countries, More Support To Countries Struggling With High Debt Service Costs; Will Keep Pressing China To Change Economic Model That Channels Too Much Savings, Too Many Subsidies Into Manufacturing, Creating Excess Capacity; U.S. Concerns Over China's Excess Capacity And Its Threats To Workers And Firms Are 'Shared By Many' At G20 Meetings

Truist Securities analyst William Stein maintains TE Connectivity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEL#NYSE">TEL</a>) with a Hold and raises the price target from $151 to $156.

Truist Securities Maintains Hold on TE Connectivity, Raises Price Target to $156

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Citigroup analyst Paul Lejuez downgraded the rating for Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) from Buy to Neutral, while cutting the price target from $415 to $300. Lululemon shares settled at $272.06 on Wednesday. <a href="https://www.benzinga.com/quote/LULU/analyst-ratings">See how other analysts view this stock. See how other analysts view this stock.</a></li>
<li>Argus Research analyst Kevin Heal downgraded Zions Bancorporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) from Buy to Hold. Zions Bancorp shares closed at $50.98 on Wednesday. <a href="https://www.benzinga.com/quote/ZION/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Travis Steed downgraded the rating for Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) from Buy to Neutral, while lowering the price target from $105 to $75. Edwards Lifesciences shares closed at $86.95 on Wednesday. <a href="https://www.benzinga.com/quote/EW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel analyst Matthew Smith downgraded Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) from Buy to Hold and slashed the price target from $115 to $60. Lamb Weston shares closed at $56.42 on Wednesday. <a href="https://www.benzinga.com/quote/LW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst Quinn Bolton downgraded the rating for MaxLinear, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) from Buy to Hold. MaxLinear shares closed at $22.29 on Wednesday. <a href="https://www.benzinga.com/quote/MXL/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39958828/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-6-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 6% Dividend Yields</a></li>
</ul>

Downgrades

LULU

ZION

This Lululemon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

U.S. Treasury's Yellen Says U.S. Q2 GDP, Inflation Data On Thursday Affirms That U.S. On Path To Steady Growth, Declining Inflation; Strong U.S. Growth Due To Biden-Harris Administration's Economic Plan, With 15.7M Jobs Created Since Taking Office; Prices Still Too High For Many Americans, Administration Working To Address Cost Pressures In Housing, Healthcare, Energy

U.S. Treasury's Yellen Says Biden Has Driven A 'Remarkable Economic Recovery,' Restored U.S. Standing In World; 'Deeply Proud' To Serve With Biden And Harris, Looks Forward To Continue Advancing U.S. Leadership Abroad, Strong Economic Results At Home; Global Economy Remains Resilient, Driven In Large Part By U.S. Economic Performance

Legal

New Delhi City Police Summons Diageo India CEO To Appear At Investigation Into Case Linked To Payments By Government Agencies For Liquor Purchases

Editor&#8217;s Note: The headline of this article was corrected; it previously mentioned Apple Earnings instead of Alphabet. Note that Apple's third-quarter earnings are scheduled for Thursday, Aug. 2.
The recent tech stock selloff has raised concerns about Wall Street&#8217;s vulnerability to a potential downturn in the Big Tech trade, prompting investors to reconsider their portfolio composition.
What Happened: The market experienced a selloff triggered by disappointing quarterly reports from Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Google-parent Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), causing the tech-heavy Nasdaq Composite to drop 3.6% in its worst day since October 2022.
Senior portfolio manager at GLOBALT, Thomas Martin, indicated that Tesla&#8217;s results served as a wake-up call for investors who realized their portfolios were heavily weighted towards information technology and growthier type companies, Reuters reported. 
&#8220;This was the hair trigger for people saying, &#8216;Wow, I&#8217;ve got way too much exposure to information technology and growthier type companies,'&#8221; he said.
&nbsp;&#8220;The trade &#8230; is to get more diversified.&#8221;
 Jake Dollarhide, chief executive officer of Longbow Asset Management, added, &#8220;We set the bar too high on earnings. Even Alphabet&#8217;s earnings beat, but the market obviously wasn&#8217;t impressed and they didn&#8217;t beat by enough.&#8221;
The selloff follows a prolonged rally in tech and growth companies, including Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), driven by optimism about artificial intelligence technology. These megacap stocks, along with Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), have accounted for approximately a third of the S&amp;P 500&#8217;s 14% gain in 2024.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39923307/senator-cynthia-lummis-slams-biden-administrations-dangerous-scheme-to-impose-30-tax-on-bi?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Senator Cynthia Lummis Slams Biden Administration&#8217;s &#8216;Dangerous Scheme&#8217; To Impose 30% Tax On Bitcoin Mining, Call It &#8216;Blatant Attack&#8217; On American Excellence</a>
However, as share prices soared, concerns grew over companies&#8217; stretched valuations, drawing comparisons to <a href="https://www.benzinga.com/top-stories/24/07/39601364/ai-surge-sparks-fears-of-dot-com-like-bubble-burst">the dot-com bubble</a> of more than two decades ago. The S&amp;P 500 is trading near 22 times expected earnings, its highest in over two years, and well above its 10-year average of 18.
Signs of nervousness around tech stocks have been evident in recent weeks, with hedge funds reducing their market exposure amid fears that gains from earlier this year could evaporate if sentiment around tech stocks changed.
However, some like Tim Ghriskey, senior portfolio strategist at New York-based Ingalls &amp; Snyder, feel the pullback is a short-term phenomenon and could reverse &#8220;if we see some good numbers in the coming days.&#8221;
Why It Matters: The recent tech selloff has had a significant impact on key tech suppliers. For instance, South Korea's SK Hynix, a major supplier to NVIDIA, saw its<a href="https://www.benzinga.com/markets/asia/24/07/39948132/key-nvidia-supplier-sk-hynix-stock-drops-nearly-8-following-us-tech-sell-off-despite-record-quarterl"> stock drop nearly 8% </a>following the U.S. tech sell-off, despite reporting its highest quarterly profit since 2018.
The disappointing earnings from mega tech companies have wiped out <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39938672/us-stocks-tumble-magnificent-7-wipe-out-570-billion-as-mega-tech-earnings-disappoint-vix-s">over $570 billion </a>in their combined market valuation, with Tesla shares plummeting over 11% after missing earnings expectations.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39883677/investors-anticipate-unraveling-of-trump-trade-as-biden-exits-presidential-race-but-analyst-says-its?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Investors Anticipate Unraveling Of &#8216;Trump Trade&#8217; As Biden Exits Presidential Race, But Analyst Says &#8216;It&#8217;s &nbsp;A Bit Too Early For The Markets To Declare Victory For Trump&#8217;</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Analyst Color

Tech

General

AMZN

GOOGL

MSFT

NVDA

TSLA

Tesla, Alphabet Selloff After Recent Earnings Was A 'Hair Trigger' For Investors To Rethink Tech-Heavy Portfolios: 'We Set The Bar Too High' (CORRECTED)

Truist Securities analyst Joel Fishbein maintains ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) with a Hold and raises the price target from $750 to $780.

Truist Securities Maintains Hold on ServiceNow, Raises Price Target to $780

Investors with a lot of money to spend have taken a bearish stance on Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MCHP, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Microchip Technology.
This isn't normal.
The overall sentiment of these big-money traders is split between 25% bullish and 75%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $507,397, and 3 are calls, for a total amount of $129,020.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $80.0 and $95.0 for Microchip Technology, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Microchip Technology's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Microchip Technology's whale trades within a strike price range from $80.0 to $95.0 in the last 30 days. 
<h3>Microchip Technology Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721918771_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCHP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$3.0</td>
<td>$1.65</td>
<td>$2.05</td>
<td>$80.00</td>
<td>$205.0K</td>
<td>2.6K</td>
<td>1.0K</td>
</tr>
<tr>
<td>MCHP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$1.9</td>
<td>$1.85</td>
<td>$1.9</td>
<td>$80.00</td>
<td>$127.1K</td>
<td>2.6K</td>
<td>1.0K</td>
</tr>
<tr>
<td>MCHP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$10.8</td>
<td>$10.7</td>
<td>$10.7</td>
<td>$92.50</td>
<td>$82.3K</td>
<td>1.5K</td>
<td>79</td>
</tr>
<tr>
<td>MCHP</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$2.0</td>
<td>$1.85</td>
<td>$1.9</td>
<td>$80.00</td>
<td>$62.8K</td>
<td>2.6K</td>
<td>2.0K</td>
</tr>
<tr>
<td>MCHP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$5.4</td>
<td>$5.2</td>
<td>$5.2</td>
<td>$90.00</td>
<td>$44.7K</td>
<td>413</td>
<td>153</td>
</tr>
</tbody>
</table>

<h3>About Microchip Technology</h3>
Microchip Technology became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Following our analysis of the options activities associated with Microchip Technology, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Microchip Technology</h3>
<ul>
<li>Trading volume stands at 2,764,871, with MCHP's price down by -1.43%, positioned at $85.33.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 7 days.</li>
</ul>
<h3>Expert Opinions on Microchip Technology</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $107.5.
<ul>
<li>Maintaining their stance, an analyst from Susquehanna continues to hold a Positive rating for Microchip Technology, targeting a price of $115. </li>
<li>In a cautious move, an analyst from Morgan Stanley downgraded its rating to Equal-Weight, setting a price target of $100. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Microchip Technology, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

MCHP

Microchip Technology Unusual Options Activity

Financial giants have made a conspicuous bearish move on Pfizer. Our analysis of options history for Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) revealed 21 unusual trades.
Delving into the details, we found 42% of traders were bullish, while 47% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $296,355, and 18 were calls, valued at $1,032,173.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $25.0 to $35.0 for Pfizer over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Pfizer's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Pfizer's whale activity within a strike price range from $25.0 to $35.0 in the last 30 days. 
<h3>Pfizer Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721918766_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$5.3</td>
<td>$5.2</td>
<td>$5.3</td>
<td>$35.00</td>
<td>$159.0K</td>
<td>86</td>
<td>300</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$0.73</td>
<td>$0.72</td>
<td>$0.72</td>
<td>$31.00</td>
<td>$121.9K</td>
<td>19.3K</td>
<td>5.3K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$2.42</td>
<td>$2.41</td>
<td>$2.42</td>
<td>$30.00</td>
<td>$106.2K</td>
<td>52.1K</td>
<td>3.4K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$0.6</td>
<td>$0.59</td>
<td>$0.6</td>
<td>$31.00</td>
<td>$101.5K</td>
<td>19.3K</td>
<td>3.1K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$2.53</td>
<td>$2.5</td>
<td>$2.53</td>
<td>$28.00</td>
<td>$89.3K</td>
<td>22.1K</td>
<td>1.2K</td>
</tr>
</tbody>
</table>

<h3>About Pfizer</h3>
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
In light of the recent options history for Pfizer, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Pfizer Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 10,278,316, the PFE's price is up by 2.22%, now at $30.64. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 5 days.</li>
</ul>
<h3>What The Experts Say On Pfizer</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $41.25.
<ul>
<li>Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Pfizer with a target price of $30. </li>
<li>An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $45. </li>
<li>An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $45. </li>
<li>In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $45. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Pfizer, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Pfizer's Options: A Look at What the Big Money is Thinking

IPOs

ORKT

Orangekloud Technology Shares Open For Trade At $5.20/Share; IPO Priced At $4.75/Share

Whales with a lot of money to spend have taken a noticeably bearish stance on Novo Nordisk.
Looking at options history for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 62% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $155,555 and 5, calls, for a total amount of $255,360.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $100.0 to $175.0 for Novo Nordisk during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Novo Nordisk's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Novo Nordisk's substantial trades, within a strike price spectrum from $100.0 to $175.0 over the preceding 30 days.
<h3>Novo Nordisk Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721918761_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$3.6</td>
<td>$3.45</td>
<td>$3.55</td>
<td>$115.00</td>
<td>$71.0K</td>
<td>100</td>
<td style="text-align: right;">4</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$5.4</td>
<td>$5.25</td>
<td>$5.25</td>
<td>$127.00</td>
<td>$66.0K</td>
<td>2</td>
<td style="text-align: right;">125</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$33.65</td>
<td>$33.3</td>
<td>$33.42</td>
<td>$100.00</td>
<td>$63.4K</td>
<td>1.4K</td>
<td style="text-align: right;">19</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$1.75</td>
<td>$1.71</td>
<td>$1.73</td>
<td>$145.00</td>
<td>$48.9K</td>
<td>8.1K</td>
<td style="text-align: right;">415</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$15.25</td>
<td>$14.4</td>
<td>$14.66</td>
<td>$125.00</td>
<td>$43.9K</td>
<td>1.0K</td>
<td style="text-align: right;">31</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
In light of the recent options history for Novo Nordisk, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Novo Nordisk</h3>
<ul>
<li>Trading volume stands at 1,568,565, with NVO's price down by -3.0%, positioned at $127.65.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 13 days.</li>
</ul>
<h3>Expert Opinions on Novo Nordisk</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $160.0.
<ul>
<li>An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $160. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Novo Nordisk, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Novo Nordisk's Options Frenzy: What You Need to Know

In a report released yesterday, Chris Lui from Jefferies maintained a Buy rating on Wuxi Biologics (Cayman) (WXIBF – Research Report), with a price...

Wuxi Biologics: A Strong Buy on Valuation and Growth Potential

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Wuxi Biologics (Cayman) (WXIBF – Research Report) ...

Analysts Offer Insights on Healthcare Companies: Wuxi Biologics (Cayman) (OtherWXIBF) and Generation Bio (GBIO)

Wuxi Biologics (Cayman) (HK:2269) has released an update. WuXi Biologics (Cayman) Inc. is proposing amendments to align its current memorandum and ...

WuXi Biologics Adopts Electronic Communication Updates

Wuxi Biologics (Cayman) (HK:2269) has released an update. WuXi Biologics (Cayman) Inc. has announced its Annual General Meeting to be held in Shang...

WuXi Biologics Announces Upcoming AGM Details

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

WuXi Biologics (Cayman)

News

Latest news for WuXi Biologics (Cayman) (OTC:WXIBF) Stock

Thursday, March 28, 2024

Friday, December 27, 2019

Monday, December 23, 2019